Association Analysis of the Plasminogen Activator Inhibitor-1 4G/5G Polymorphism in Hispanics and African Americans: The IRAS Family Study
- 1 August 2004
- journal article
- research article
- Published by S. Karger AG in Human Heredity
- Vol. 57 (3) , 128-137
- https://doi.org/10.1159/000079243
Abstract
Objective: Plasminogen activator inhibitor type-1 (PAI-1) plays a central role in fibrolysis and has recently been hypothesized to influence components of the insulin resistance syndrome. We consider whether the 4G/5G polymorphism influences components of insulin resistance and obesity solely through PAI-1 protein levels or also though a secondary pathway. In addition, we explore whether transforming growth factor (TGF-β1), a key regulator of PAI-1 expression, modifies the influence of the PAI-1 4G/5G polymorphism on these traits. Methods and Results: The Insulin Resistance and Atherosclerosis (IRAS) Family Study genotyped 287 African American (18 pedigrees) and 811 Hispanic American (45 pedigrees) individuals for the 4G/5G PAI-1 and two TGF-β1 polymorphisms (R25P, C-509T). Individuals were recruited from three clinical centers located in San Antonio (urban Hispanic), San Luis Valley (rural Hispanic) and Los Angeles (African American). The presence of the 4G PAI-1 allele was positively associated with PAI-1 protein level (combined sample p < 0.0001). Hispanic Americans average 65% higher PAI-1 protein levels than African Americans (p < 0.0001). Consistently across ethnic groups, increased PAI-1 protein levels were associated with increased insulin resistance and overall and central obesity (p value < 0.0001, combined sample). Adjusting for PAI-1 protein levels, there was evidence of an association of PAI-1 genotype (4G) with insulin sensitivity (p < 0.002) and subcutaneous fat (p < 0.01). These associations were not influenced by TGF-β1 genotypes. Conclusions: PAI-1 protein is a strong correlate of insulin resistance (IR) and obesity in Hispanics and African Americans. However, PAI-1 4G/5G polymorphism appears to influence insulin resistance and obesity beyond its direct influence on serum PAI-1 protein levels.Keywords
This publication has 19 references indexed in Scilit:
- Promoter (4G/5G) Plasminogen Activator Inhibitor-1 Genotype and Plasminogen Activator Inhibitor-1 Levels in Blacks, Hispanics, and Non-Hispanic WhitesCirculation, 2003
- Genetic Epidemiology of Insulin Resistance and Visceral Adiposity The IRAS Family Study Design and MethodsAnnals of Epidemiology, 2003
- Association of angiotensin converting enzyme and plasminogen activator inhibitor-1 promoter gene polymorphisms with features of the insulin resistance syndrome in patients with premature coronary heart diseaseAtherosclerosis, 2001
- Regulation of Plasminogen Activator Inhibitor-1 Expression by Transforming Growth Factor-β-induced Physical and Functional Interactions between Smads and Sp1Journal of Biological Chemistry, 2000
- Analysis of genetic polymorphisms in the transforming growth factor-?1 gene and the risk of Alzheimer's diseaseHuman Genetics, 2000
- Statistical Tests for Detection of Misspecified Relationships by Use of Genome-Screen DataAmerican Journal of Human Genetics, 2000
- Synthesis and Secretion of Plasminogen Activator Inhibitor-1 by Human PreadipocytesJournal of Clinical Endocrinology & Metabolism, 1999
- Familiality of Quantitative Metabolic Traits in Finnish Families with Non-Insulin-Dependent Diabetes mellitusHuman Heredity, 1999
- Smad4/DPC4 and Smad3 Mediate Transforming Growth Factor-β (TGF-β) Signaling through Direct Binding to a Novel TGF-β-responsive Element in the Human Plasminogen Activator Inhibitor-1 PromoterPublished by Elsevier ,1998
- PedCheck: A Program for Identification of Genotype Incompatibilities in Linkage AnalysisAmerican Journal of Human Genetics, 1998